Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neural Effects of Cannabinoid CB1 Neutral Antagonist Tetrahydrocannabivarin on Food Reward and Aversion in Healthy Volunteers
Luke Tudge, Clare Williams, Philip J. Cowen, et al.
The International Journal of Neuropsychopharmacology (2015) Vol. 18, Iss. 6
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Phytocannabinoids: a unified critical inventory
L Hanŭs, Stefan Meyer, Eduardo Muñóz, et al.
Natural Product Reports (2016) Vol. 33, Iss. 12, pp. 1357-1392
Open Access | Times Cited: 736
From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Alessia Ligresti, Luciano De Petrocellis, Vincenzo Di Marzo
Physiological Reviews (2016) Vol. 96, Iss. 4, pp. 1593-1659
Open Access | Times Cited: 414
The Pharmacological Case for Cannabigerol
Rahul Nachnani, Wesley M. Raup‐Konsavage, Kent E. Vrana
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 376, Iss. 2, pp. 204-212
Open Access | Times Cited: 149
Cannabinoid Receptors: An Update on Cell Signaling, Pathophysiological Roles and Therapeutic Opportunities in Neurological, Cardiovascular, and Inflammatory Diseases
Dhanush Haspula, Michelle A. Clark
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 20, pp. 7693-7693
Open Access | Times Cited: 100
Minor Cannabinoids: Biosynthesis, Molecular Pharmacology and Potential Therapeutic Uses
Kenneth B. Walsh, Amanda E. McKinney, Andrea E. Holmes
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 95
Overcoming the Psychiatric Side Effects of the Cannabinoid CB1 Receptor Antagonists: Current Approaches for Therapeutics Development
Thuy Nguyen, Brian F. Thomas, Yanan Zhang
Current Topics in Medicinal Chemistry (2019) Vol. 19, Iss. 16, pp. 1418-1435
Open Access | Times Cited: 85
Great Expectations: A Critical Review of and Suggestions for the Study of Reward Processing as a Cause and Predictor of Depression
Dylan M. Nielson, Hanna Keren, Georgia O’Callaghan, et al.
Biological Psychiatry (2020) Vol. 89, Iss. 2, pp. 134-143
Open Access | Times Cited: 70
Integrative Hedonic and Homeostatic Food Intake Regulation by the Central Nervous System: Insights from Neuroimaging
Alejandro Campos, John D. Port, Andrés Acosta
Brain Sciences (2022) Vol. 12, Iss. 4, pp. 431-431
Open Access | Times Cited: 46
The effect of five day dosing with THCV on THC-induced cognitive, psychological and physiological effects in healthy male human volunteers: A placebo-controlled, double-blind, crossover pilot trial
Amir Englund, Zerrin Atakan, Aleksandra Kralj, et al.
Journal of Psychopharmacology (2015) Vol. 30, Iss. 2, pp. 140-151
Closed Access | Times Cited: 78
Δ9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes
Amos Olusegun Abioye, Oladapo Ayodele, Aleksandra Marinkovic, et al.
Journal of Cannabis Research (2020) Vol. 2, Iss. 1
Open Access | Times Cited: 66
Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation?
Natalie E. Zlebnik, Joseph F. Cheer
Annual Review of Neuroscience (2016) Vol. 39, Iss. 1, pp. 1-17
Open Access | Times Cited: 65
Anhedonia in chronic pain and prescription opioid misuse
Eric L. Garland, Martin Trøstheim, Marie Eikemo, et al.
Psychological Medicine (2019) Vol. 50, Iss. 12, pp. 1977-1988
Open Access | Times Cited: 63
The endocannabinoidome as a substrate for noneuphoric phytocannabinoid action and gut microbiome dysfunction in neuropsychiatric disorders
Vincenzo Di Marzo
Dialogues in Clinical Neuroscience (2020) Vol. 22, Iss. 3, pp. 259-269
Open Access | Times Cited: 61
Opportunities, Challenges, and Scientific Progress in Hemp Crops
Kacper Piotr Kaminski, Julia Hoeng, Fernando Goffman, et al.
Molecules (2024) Vol. 29, Iss. 10, pp. 2397-2397
Open Access | Times Cited: 6
Affective value, intensity and quality of liquid tastants/food discernment in the human brain: An activation likelihood estimation meta-analysis
Andy Wai Kan Yeung, Tazuko K. Goto, WK Leung
NeuroImage (2017) Vol. 169, pp. 189-199
Closed Access | Times Cited: 58
Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders
Ewa Galaj, Zheng‐Xiong Xi
CNS Drugs (2019) Vol. 33, Iss. 10, pp. 1001-1030
Open Access | Times Cited: 50
Pharmacological potential of varinic-, minor-, and acidic phytocannabinoids
Rafael Franco, Rafael Rivas‐Santisteban, Irene Reyes‐Resina, et al.
Pharmacological Research (2020) Vol. 158, pp. 104801-104801
Closed Access | Times Cited: 40
Altered neural responsivity to food cues in relation to food preferences, but not appetite-related hormone concentrations after RYGB-surgery
H.F.A. Zoon, Suzanne E.M. de Bruijn, Paul A.M. Smeets, et al.
Behavioural Brain Research (2018) Vol. 353, pp. 194-202
Open Access | Times Cited: 46
The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers
Ewelina Rzepa, Luke Tudge, Ciara McCabe
The International Journal of Neuropsychopharmacology (2015) Vol. 19, Iss. 2, pp. pyv092-pyv092
Open Access | Times Cited: 40
Enhanced neural response to anticipation, effort and consummation of reward and aversion during bupropion treatment
Zola Dean, Stefanie Horndasch, Panagiotis G. Giannopoulos, et al.
Psychological Medicine (2016) Vol. 46, Iss. 11, pp. 2263-2274
Closed Access | Times Cited: 33
Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence
Yann Chye, Rebecca Kirkham, Valentina Lorenzetti, et al.
Biological Psychiatry Cognitive Neuroscience and Neuroimaging (2020) Vol. 6, Iss. 6, pp. 627-635
Closed Access | Times Cited: 31
Minor Phytocannabinoids: A Misleading Name but a Promising Opportunity for Biomedical Research
Diego Caprioglio, Hawraz Ibrahim M. Amin, Orazio Taglialatela‐Scafati, et al.
Biomolecules (2022) Vol. 12, Iss. 8, pp. 1084-1084
Open Access | Times Cited: 17
Neutral CB1 Receptor Antagonists as Pharmacotherapies for Substance Use Disorders: Rationale, Evidence, and Challenge
Omar Soler‐Cedeño, Zheng‐Xiong Xi
Cells (2022) Vol. 11, Iss. 20, pp. 3262-3262
Open Access | Times Cited: 16
The Development of Cannabinoids as Therapeutic Agents in the United States
Conor H. Murray, Brenda M. Gannon, Peter J. Winsauer, et al.
Pharmacological Reviews (2024) Vol. 76, Iss. 5, pp. 915-955
Open Access | Times Cited: 3
Neuroimaging studies towards understanding the central effects of pharmacological cannabis products on patients with epilepsy
Jane B. Allendorfer, Jerzy P. Szaflarski
Epilepsy & Behavior (2017) Vol. 70, pp. 349-354
Closed Access | Times Cited: 30
Page 1 - Next Page

Scroll to top